Literature DB >> 34409523

Therapeutic Potential of Curcumin in Reversing the Depression and Associated Pseudodementia via Modulating Stress Hormone, Hippocampal Neurotransmitters, and BDNF Levels in Rats.

Asia Afzal1, Zehra Batool2, Sadia Sadir1, Laraib Liaquat3, Sidrah Shahzad1,4, Saiqa Tabassum5, Saara Ahmad6, Noor Kamil7, Tahira Perveen1, Saida Haider1.   

Abstract

Depressive state adversely affects the memory functions, especially in the geriatric population. The initial stage of memory deficits associated with depression is particularly called as pseudodementia. It is the starting point of memory disturbance before dementia. The purpose of this research was to study depression and its consequent pseudodementia. For this purpose 24 male albino Wistar rats were divided into four groups. Depression was induced by 14 days of chronic restraint stress (CRS) daily for 4 h. After developing a depression model, pattern separation test was conducted to monitor pseudodementia in rats. Morris water maze test (MWM) was also performed to observe spatial memory. It was observed that model animals displayed impaired pattern separation and spatial memory. Treatment was started after the development of pseudodementia in rats. Curcumin at a dose of 200 mg/kg was given to model rats for one week along with the stress procedure. Following the treatment with curcumin, rats were again subjected to the aforementioned behavioral tests before decapitation. Corticosterone levels, brain derived neurotrophic factor (BDNF) and neurochemical analysis were conducted. Model rats showed depressogenic behavior and impaired memory performance. In addition to this, high corticosterone levels and decreased hippocampal BDNF, 5-HT, dopamine (DA), and acetylcholine (ACh) levels were also observed in depressed animals. These behavioral biochemical and neurochemical changes were effectively restored following treatment with curcumin. Hence, it is suggested from this study that pseudodementia can be reversed unlike true dementia by controlling the factors such as depression which induce memory impairment.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acetylcholine; BDNF; Corticosterone; Curcumin; Monoamines; Pseudodementia

Mesh:

Substances:

Year:  2021        PMID: 34409523     DOI: 10.1007/s11064-021-03430-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  54 in total

1.  Administration of 5-HT-1B agonist ameliorates pseudodementia induced by depression in rats.

Authors:  Asia Afzal; Saara Ahmad; Faiza Agha; Zehra Batool; Saiqa Tabassum; Laraib Liaquat; Sadia Sadir; Amber Nawaz; Saida Haider
Journal:  Pak J Pharm Sci       Date:  2018-09       Impact factor: 0.684

Review 2.  Diagnosis and treatment of depression and cognitive impairment in late life.

Authors:  Sarah Shizuko Morimoto; Dora Kanellopoulos; Kevin J Manning; George S Alexopoulos
Journal:  Ann N Y Acad Sci       Date:  2015-02-05       Impact factor: 5.691

3.  Cognitive impairment in schizophrenia and depression: A comparison of stability and course.

Authors:  Peter Neu; Tina Gooren; Ulrike Niebuhr; Peter Schlattmann
Journal:  Appl Neuropsychol Adult       Date:  2017-11-21       Impact factor: 2.248

Review 4.  Depression and risk of developing dementia.

Authors:  Amy L Byers; Kristine Yaffe
Journal:  Nat Rev Neurol       Date:  2011-05-03       Impact factor: 42.937

5.  Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins.

Authors:  Jessica A Brommelhoff; Margaret Gatz; Boo Johansson; John J McArdle; Laura Fratiglioni; Nancy L Pedersen
Journal:  Psychol Aging       Date:  2009-06

Review 6.  Epigenetic mechanisms of major depression: Targeting neuronal plasticity.

Authors:  Shusaku Uchida; Hirotaka Yamagata; Tomoe Seki; Yoshifumi Watanabe
Journal:  Psychiatry Clin Neurosci       Date:  2017-12-26       Impact factor: 5.188

7.  A mouse model of depression induced by repeated corticosterone injections.

Authors:  Yunan Zhao; Ru Ma; Jia Shen; Hui Su; Dongming Xing; Lijun Du
Journal:  Eur J Pharmacol       Date:  2007-12-14       Impact factor: 4.432

Review 8.  Pseudo-dementia: A neuropsychological review.

Authors:  Hai Kang; Fengqing Zhao; Llbo You; Cinzia Giorgetta; Venkatesh D; Sujit Sarkhel; Ravi Prakash
Journal:  Ann Indian Acad Neurol       Date:  2014-04       Impact factor: 1.383

9.  Increased corticosterone in peripubertal rats leads to long-lasting alterations in social exploration and aggression.

Authors:  Vandana Veenit; Maria I Cordero; Stamatina Tzanoulinou; Carmen Sandi
Journal:  Front Behav Neurosci       Date:  2013-04-04       Impact factor: 3.558

Review 10.  Dopamine System Dysregulation in Major Depressive Disorders.

Authors:  Pauline Belujon; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2017-12-01       Impact factor: 5.176

View more
  4 in total

Review 1.  St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?

Authors:  Gita Kholghi; Shirin Arjmandi-Rad; Mohammad-Reza Zarrindast; Salar Vaseghi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-16       Impact factor: 3.000

2.  Associations Between Disordered Microbial Metabolites and Changes of Neurotransmitters in Depressed Mice.

Authors:  Jing Xie; Ying Wang; Qi Zhong; Shun-Jie Bai; Chan-Juan Zhou; Tian Tian; Jian-Jun Chen
Journal:  Front Cell Infect Microbiol       Date:  2022-05-20       Impact factor: 6.073

Review 3.  Potential Role of Curcumin for the Treatment of Major Depressive Disorder.

Authors:  Adrian L Lopresti
Journal:  CNS Drugs       Date:  2022-02-07       Impact factor: 5.749

Review 4.  An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders.

Authors:  Nicolás Lamanna-Rama; Diego Romero-Miguel; Manuel Desco; Maria Luisa Soto-Montenegro
Journal:  Antioxidants (Basel)       Date:  2022-02-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.